[Single-blind study of the efficacy of pirozadil versus alufibrate in the treatment of primary hyperlipoproteinemias].
Pirozadil and alufibrate are compared by a single-blind study over two groups 20 patients with primary hyperlipoproteinemia. Pirozadil seems more effective as a cholesterol-lowering agent. There were no adverse reactions. We conclude that pirozadil can be a valuable agent in preventing atherosclerotic disease.
D002784:Cholesterol / Q000097:blood; D002994:Clofibrate / Q000031:analogs & derivatives*; D002995:Clofibric Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D006951:Hyperlipoproteinemias / Q000097:blood / Q000188:drug therapy*; D008074:Lipoproteins / Q000097:blood; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects; D011725:Pyridines / Q000627:therapeutic use*; D011897:Random Allocation
D008074:Lipoproteins; D011725:Pyridines; C005681:alfibrate; D002995:Clofibric Acid; C015453:pirozadil; D002784:Cholesterol; D002994:Clofibrate
Estudio simple ciego sobre la eficacia del pirozadil versus alufibrato en el tratamiento de las hiperlipoproteinemias primarias.